# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-Reuters
Wells Fargo analyst Brandon Couillard initiates coverage on Maravai LifeSciences (NASDAQ:MRVI) with a Overweight rating and ...
Wall Street edged slightly higher on Friday, with major equity indices showing modest gains at midday in New York.
- Reuters Citing Sources
RBC Capital analyst Conor McNamara reiterates Maravai LifeSciences (NASDAQ:MRVI) with a Outperform and maintains $15 price t...
Morgan Stanley analyst Tejas Savant downgrades Maravai LifeSciences (NASDAQ:MRVI) from Overweight to Equal-Weight and lowers...
Goldman Sachs analyst Matthew Sykes maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target ...